CLARUS THERAPEUTICS HOLDINGS (CRXT) Stock Price, Quote, News and Overview
NASDAQ:CRXT - Nasdaq - US18271L1070 - Common Stock - Currency: USD
CRXT Quote, Performance and Key Statistics
0.099
-0.06 (-36.94%)
The current stock price of CRXT is 0.099 USD. In the past month the price decreased by -66.21%.
CRXT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.95 | 838.60B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.08 | 400.13B | ||
| JNJ | JOHNSON & JOHNSON | 16.43 | 395.10B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.72 | 232.01B | ||
| MRK | MERCK & CO. INC. | 11.96 | 231.17B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.81 | 216.53B | ||
| PFE | PFIZER INC | 8.48 | 149.50B | ||
| SNY | SANOFI-ADR | 13.48 | 135.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.43 | 116.60B | ||
| GSK | GSK PLC-SPON ADR | 7.88 | 75.71B | ||
| ZTS | ZOETIS INC | 27.65 | 73.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.08 | 44.75B |
Related stock screener links
About CRXT
Company Profile
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.
Company Info
CLARUS THERAPEUTICS HOLDINGS
555 Skokie Boulevard, Suite 340
Northbrook ILLINOIS US
CEO: Joseph Hernandez
Employees: 16
Company Website: https://clarustherapeutics.com/
Phone: 16463030737.0
CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ
What is the stock price of CLARUS THERAPEUTICS HOLDINGS today?
The current stock price of CRXT is 0.099 USD. The price decreased by -36.94% in the last trading session.
What is the ticker symbol for CLARUS THERAPEUTICS HOLDINGS stock?
The exchange symbol of CLARUS THERAPEUTICS HOLDINGS is CRXT and it is listed on the Nasdaq exchange.
On which exchange is CRXT stock listed?
CRXT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CLARUS THERAPEUTICS HOLDINGS stock?
9 analysts have analysed CRXT and the average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099. Check the CLARUS THERAPEUTICS HOLDINGS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CLARUS THERAPEUTICS HOLDINGS worth?
CLARUS THERAPEUTICS HOLDINGS (CRXT) has a market capitalization of 5.15M USD. This makes CRXT a Nano Cap stock.
How many employees does CLARUS THERAPEUTICS HOLDINGS have?
CLARUS THERAPEUTICS HOLDINGS (CRXT) currently has 16 employees.
Is CLARUS THERAPEUTICS HOLDINGS (CRXT) expected to grow?
The Revenue of CLARUS THERAPEUTICS HOLDINGS (CRXT) is expected to grow by 35.11% in the next year. Check the estimates tab for more information on the CRXT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRXT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRXT, evaluating the profitability, health, valuation and growth aspects
- CLARUS THERAPEUTICS HOLDINGS (CRXT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CLARUS THERAPEUTICS HOLDINGS (CRXT) Sales and EPS estimates to see what analysts future expectations are.
- CLARUS THERAPEUTICS HOLDINGS (CRXT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CLARUS THERAPEUTICS HOLDINGS (CRXT) Insider and Institutional Ownership to learn about the owners and their transactions.
- CLARUS THERAPEUTICS HOLDINGS (CRXT) Stock Chart to make your own analysis
- CLARUS THERAPEUTICS HOLDINGS (CRXT) Latest news and press-releases to stay up to date.
Does CLARUS THERAPEUTICS HOLDINGS (CRXT) stock pay dividends?
CRXT does not pay a dividend.
What is the Price/Earnings (PE) ratio of CLARUS THERAPEUTICS HOLDINGS (CRXT)?
CLARUS THERAPEUTICS HOLDINGS (CRXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).
CRXT Technical Analysis
CRXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRXT. Both the profitability and financial health of CRXT have multiple concerns.
CRXT Financial Highlights
Over the last trailing twelve months CRXT reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -193% | ||
| ROA | -66.68% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CRXT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CRXT. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 87.39% and a revenue growth 35.11% for CRXT